SV Health Investors and Genesys Capital have co-led a series A round for University of Toronto’s EBT Medical, which is progressing a neuromodulation technique to treat pelvic floor disorders.

EBT Medical, a Canada-based neuromodulation technology spinout of University of Toronto, has procured $10m in a series A round co-led by venture capital firms SV Health Investors and Genesys Capital.
Founded in 2014, EBT is working on a wearable neuromodulation-based treatment for pelvic floor disorders triggered by pudendal nerve damage which causes the bladder to become overactive.
EBT’s device would be discreet and minimally invasive, in the hope of supplanting existing drugs and surgical procedures. The concept works…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?